about
Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventionsNeointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study.Culprit lesion thrombus burden after manual thrombectomy or percutaneous coronary intervention-alone in ST-segment elevation myocardial infarction: the optical coherence tomography sub-study of the TOTAL (ThrOmbecTomy versus PCI ALone) trialInvasive Hemodynamic Assessment of Cardiac Output State after MitraClip Therapy in Nonanaesthetized Patients with Functional Mitral Regurgitation.Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'Absorb bioresorbable stents for the treatment of coronary artery disease.Manual aspiration thrombectomy devices use in coronary interventions in 2016.Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update.One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: The PRAGUE-19 Study.Transcatheter aortic valve implantation: long-term clinical outcome and valve durability.Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a cliHeart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis.Five year two center retrospective analysis of patients with toxic digoxin serum concentration.Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease.ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison.High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel.Two-year follow-up after bioresorbable vascular scaffold implantation in STEMI patients - Results from PRAGUE-19 study.Degenerative changes and immune response after transcatheter aortic valve implantation. Comparison with surgical aortic valve replacement.Successful treatment of massive pulmonary embolism with prolonged catheter-directed thrombolysis.Takotsubo Cardiomyopathy: One More Angiographic Evidence of Microvascular Dysfunction.Platelet-derived chemokines, PF-4 and RANTES, are significantly increased in hemodynamically significant degenerative aortic stenosisIbutilide-induced cardioversion of atrial fibrillation during pregnancy.Cardiac resynchronization therapy for the causal treatment of heart failure with preserved ejection fraction: insight from a pressure-volume loop analysisPredictors of improvement of unrepaired moderate ischemic mitral regurgitation in patients undergoing elective isolated coronary artery bypass graft surgeryCardiac resynchronization therapy implantation following transcatheter aortic valve implantationST elevation myocardial infarction treated with bioresorbable vascular scaffold: rationale and first casesPotential role of invariant natural killer T cells in outcomes of acute myocardial infarctionRelationship between TRAIL and Left Ventricular Ejection Fraction in Patients with ST-Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention
P50
Q26740181-44D8554B-9C96-4C27-A926-495E780BB088Q35610359-8108F700-6D53-4945-8FA7-119B8DFD8D24Q37334624-8BDBE910-1C63-4224-94E4-394E05435702Q37531781-7F6A8236-36B3-4642-8708-AE96E29F44C5Q37671897-0D070629-EB83-4C21-A75C-FF891B2C1911Q38573540-F3F9EA1E-D725-4E1F-8D55-AEAA54CFB788Q38710950-C0108557-DEAF-4AE7-8272-3B6FC1F5EB75Q39770662-377F3C1A-4F89-4B64-B7E2-C6CDB5BF56EEQ40250978-5AAE3552-73EC-45ED-8F79-977EB180EC0DQ40776685-659A1E84-6925-4161-AADF-0BFC921E4B99Q41533817-760A869E-8CE8-4BCE-ADD2-5770419C0170Q43098212-B074B70E-6ED5-478C-9E1A-F047591660DEQ44570666-34CB1D55-64C8-466E-94C3-26A5A9BEF592Q46265497-939F42CD-DBC6-4609-9E5E-F3D1891EDBEBQ51364161-6937E530-2B53-4A69-8CC1-F4FD5FF26923Q51373561-8824030B-B59F-4F03-99C8-4BCB486BE33BQ51522406-615854E0-5E1B-412F-945C-2A1DCF2F6892Q52983374-977FBA11-5269-46C4-8EF2-4C0D4C8097F2Q53546266-26084DEB-08AA-4DFC-9137-E098444607F3Q55004986-BCD6E0A3-B1F8-453A-8534-8AA28DC96C63Q60432754-8BB38048-F01A-49B3-BD48-81866CC8C9B5Q64971356-518181C7-92A2-4FB0-AEAB-515F26AE90F3Q84144067-93BA3360-798C-4E85-BEE1-6F8DA5569A21Q84592582-DE33600B-A5DE-4450-8101-67F999C4684FQ85049933-A0E8E65B-E8BB-4C64-BFDE-5E49D21A0DF6Q86887069-BB86D670-6D9B-42BF-B7AD-40FC2F5F9093Q87127054-6B707F80-664C-418F-A2E7-D5A1DED20ADBQ90969691-5B1DC99E-36CA-41FE-BA55-762878D1D716
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Viktor Kočka
@ast
Viktor Kočka
@en
Viktor Kočka
@es
Viktor Kočka
@nl
Viktor Kočka
@sl
type
label
Viktor Kočka
@ast
Viktor Kočka
@en
Viktor Kočka
@es
Viktor Kočka
@nl
Viktor Kočka
@sl
prefLabel
Viktor Kočka
@ast
Viktor Kočka
@en
Viktor Kočka
@es
Viktor Kočka
@nl
Viktor Kočka
@sl
P1053
K-7552-2017
P106
P31
P3829
P496
0000-0002-2806-0545